Visiongain Publishes Antihypertensive Drugs Market Report 2021-2031
13 November 2020
Visiongain has published a new report on Antihypertensive Drugs Market Report 2021-2031: Forecasts By Drug (Diuretics, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Beta-blockers, Vasodilators, Calcium Channel Blockers, Renin Inhibitors, Alpha-blockers and Others), By Condition (Primary Hypertension and Secondary Hypertension), By Medication type (Monotherapy, Combination Therapy and Fixed Dose Combinations), By Drug Type (Generic Drugs and Branded Drugs), By Patient Demographics (Geriatric Patient, Adult Patient and Pediatric), By End-User (Hospitals, Homecare, Specialty Clinics and Others), By Distribution Channel (Hospital Pharmacy, Retail pharmacy, Ecommerce and Others), PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Antihypertensive Drugs market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Antihypertensive Drugs market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Antihypertensive Drugs Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Antihypertensive Drugs market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Increasing prevalence of Hypertensive
Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly from last few years. Hypertensive can occur due to consumption of tobacco, too much salt (sodium) and little potassium in your diet, alcohol and to people being overweight or obese. Increasing prevalence of hypertensive are increasing demand of antihypertensive drugs for the treatment of hypertensive.
Increasing Strategic initiatives in Antihypertensive Drugs market
Antihypertensive drugs market is recoding various strategic initiatives from the player present in the market and from the manufactures who are planning to enter in the market. Manufactures in the market has formed various partnerships and joint venture to launch new product acquiring new regulatory approvals. These strategic initiatives have increased their revenue generation and helped manufacturers to increase their market share in antihypertensive drugs in the market.
Increasing Awareness Program
Increasing burden of hypertensive is leading various governments, regulatory authorities, national & international organisations to increase awareness campaigns, advertisements and press conference and social event to increase awareness regarding hypertensive treatments. These awareness programs are expected to increase the treatment and diagnosis rate in the developing countries and demand of antihypertensive drugs for hypertensive treatment.
Increasing therapeutic Advancements in Antihypertensive Drugs
Researchers and manufactures from all over the world are increasing research and development activities for development of new, innovative, more effective and economic antihypertensive drugs. New research and development will lead to introduction of new products in the market which is expected to increase the adoption of antihypertensive drugs.
Top companies (Pfizer Inc., Sanofi S.A, Novartis AG, and Boehringer Ingelheim GmbH) constitute more than XX% share of the global Antihypertensive Drugs market. Other companies profiled in the report include: Actelion Ltd., F. Hoffmann-La Roche Ltd., Bayer AG, Glenmark Pharmaceutical Inc., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, AstraZeneca plc, Lupin, Merck & Co., Inc., and Sun Pharmaceutical Industries Ltd. among others. Some of the key developments are listed below:
• In 2020, UnitedHealth has launched digital clinical trial to check impact of Angiotensin-converting enzyme (ACE) inhibitors on high-risk COVID-19 patients. The major focus of this clinical trial is to address clinical community concerns such as “these drugs would make the virus worse”, clinical train Negative impact will help to reduce fear associated with antihypertensive drugs and will boost the demand of Antihypertensive Drugs.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033